Voted Massachusetts Ten Leading Litigators — The National Law JournalCURRENT ROLEPartner & Executive Committee Member, Hagens Berman Sobol Shapiro LLPLeads HBSS’s Boston officeLead negotiator in court-approved settlements totaling more than $2 billionCourt-appointed lead or co-lead in ten active antitrust cases alleging injury to businesses and/or consumers caused by the delayed availability of generic drug, including:In re Glumetza Antitrust Litigation, No. 19-cv-05822-WHA (N.D. Cal.) (Hon.
William Alsup)FWK Holdings LLC v. Shire (Intuniv), No. 16-cv-12653 (D.
Mass.) (Hon. Allison D. Burroughs)In re Zetia (Ezetimibe) Antitrust Litigation, No.
18-md-2836 (E.D. Va.) (Hon. Rebecca Beach Smith)RECENT SUCCESS$120 million: direct purchaser class settlement, In re Loestrin 24 Fe Antitrust Litigation, No.
13-md-02472 (D.R.I.) (Hon. William E. Smith)$51.25 million: direct purchaser class settlement, In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, No.
18-md-02819 (E.D.N.Y.) (Hon. Nina Gershon)$166 million: direct purchaser class settlement, In re Lidoderm Antitrust Litigation, MDL No. 2521 (N.D.
Cal.) (Hon. William Orrick)$72.5 million: direct purchaser class settlement, In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation, No. 14-md-02503 (D.
Mass.) (Hon. Denise J. Casper)$94 million: direct purchaser class settlement, In re Celebrex (Celecoxib) Antitrust Litigation, No.
14-cv-00361 (E.D. Va.) (Hon. Arenda L.
Wright Allen, Hon. Douglas E. Miller)$146 million: direct purchaser class settlement, In re Aggrenox Antitrust Litigation, MDL No.
2516 (D. Conn.) (Hon. Stefan Underhill)CAREER HIGHLIGHTS$453.85 million: largest U.S.
antitrust settlement in 2022, In Re Glumetza Antitrust Litigation, No. 1:19-md-05822-WHA (N.D.C) (Hon. William Alsup)$340 million: second largest antitrust settlement in 2022, In re: Ranbaxy Generic Drug Application Antitrust Litigation, No.
1:19-md-02878, (D. Mass.) (Gorton, J., Kelley, J.)$325 million: third party payer class settlement, In re Neurontin Marketing, Sales Practices, and Products Liability Litigation, No. 04-md-1629 (D.
Mass) (Hon. Patti B. Saris)Approximately $200 million: tort victim recoveries via bankruptcy plan, In re New England Compounding Pharmacy, Inc.
Products Liability Litigation, MDL No. 2419 (D. Mass.) (Hon.
Rya W. Zobel)$150 million: direct purchaser class settlement, In re Flonase Antitrust Litigation, No. 08-cv-03149 (E.D.
Pa.) (Hon. Anita B. Brody)4% price reduction of most retail drugs: New England Carpenters Health Benefits Fund v.
First DataBank, Inc., No. 05-cv-11148 (D. Mass.) (Hon.
Patti B. Saris)$350 million: consumers and third party payers, San Francisco Health Plan v. McKesson Corp., No.
08-cv-10843 (D. Mass.) (Hon. Patti B.
Saris)$25 million: State of Connecticut, In re Zyprexa Products Liability Litigation, MDL No. 1596 (E.D.N.Y.) (Hon. Jack B.
Weinstein)EXPERIENCEHas led almost 20 generic delay cases, involving various theories, on behalf of both direct and end payers to settlement and distributions to classes (or aggregated groups)Helped develop the econometric model used to show the relationship between marketing and the opioid epidemic in the opioids MDL. In re National Prescription Opiate Litigation, No. 17-md-02804 (N.D.
Ohio) (Hon. Dan Aaron Polster)Originated the Ranbaxy fraudulent ANDA litigation, alleging novel theory that a generic company’s fraudulent statements to FDA in order to obtain exclusivities violated federal RICO and antitrust laws, Meijer, Inc. v.
Ranbaxy Inc., No. 15-cv-11828 (D. Mass.) (Hon.
Nathaniel M. Gorton)Served as Lead counsel in the New England Compounding MDL and a member of the creditors’ committee in the related bankruptcy, representing more than 700 victims who contracted fungal meningitis or other serious health problems as a result of receiving contaminated products produced, resulting in about a $200 million settlement, In re New England Compounding Pharmacy, Inc. Products Liability Litigation, MDL No.
2419 (D. Mass.) (Hon. F.
Dennis Saylor, IV; Hon. Rya W. Zobel)In the Vioxx MDL, developed a win-win lien resolution program for consumers and health plans that dispensed with the inefficiencies of resolving insurance liens piecemeal that is now a routine part of mass tort MDLs, In re Vioxx Products Liability Litigation, MDL No.
1657 (E.D. La.) (Hon. Eldon E.
Fallon)Obtained a $142 million RICO jury verdict against Pfizer for fraudulently marketing its drug Neurontin; negotiated a separate $325 million settlement on behalf of a class of health plans, In re Neurontin Marketing, Sales Practices, and Products Liability Litigation, MDL No. 1629 (D. Mass) (Hon.
Patti B. Saris)Brought ground-breaking suit alleging widespread fraudulent marketing and sales practices for the prostate cancer drug Lupron (In re Lupron Marketing and Sales Practices Litigation, No. 01-md-1430 (D.
Mass.) (Hon. Richard Stearns), which uncovered pricing theories later litigated in the Average Wholesale Price litigation (In re Pharmaceutical Industries Average Wholesale Price Litigation, No. 02-md-1456 (D.
Mass) (Hon. Patti B. Saris), over $250 million in settlements) and related litigation against First Databank, (New England Carpenters Health Benefits Fund v.
Patti B. Saris), major price rollback on hundreds of drugs)Worked closely with consumer groups trying to bring down the prices of prescription drugs, including serving as lead counsel to the former Prescription Access Litigation (PAL) project, a large coalition of health care advocacy groups that fought illegal, loophole-based overpricing by pharmaceutical companies.Since 2002, has represented consumers, consumer groups, health plans, governments and institutions in complex class actions involving waste, fraud, and abuse in the pharmaceutical industry.Special Assistant Attorney General for the Commonwealth of Massachusetts and the states of New Hampshire and Rhode Island, including in ground-breaking litigation against tobacco industry (injunctive relief and recovery of more than $10 billion).Spent seventeen years at a large Boston firm handling large complex civil and criminal litigation. Voted Massachusetts Ten Leading Litigators — The National Law JournalCURRENT ROLEPartner & Executive Committee Member, Hagens Berman Sobol Shapiro LLPLeads HBSS’s Boston officeLead negotiator in court-approved settlements totaling more than $2 billionCourt-appointed lead or co-lead in ten active antitrust cases alleging injury to businesses and/or consumers caused by the delayed availability of generic drug, including:In re Glumetza Antitrust Litigation, No.
19-cv-05822-WHA (N.D. Cal.) (Hon. William Alsup)FWK Holdings LLC v.
Shire (Intuniv), No. 16-cv-12653 (D. Mass.) (Hon.
Allison D. Burroughs)In re Zetia (Ezetimibe) Antitrust Litigation, No. 18-md-2836 (E.D.
Va.) (Hon. Rebecca Beach Smith)RECENT SUCCESS$120 million: direct purchaser class settlement, In re Loestrin 24 Fe Antitrust Litigation, No. 13-md-02472 (D.R.I.) (Hon.
William E. Smith)$51.25 million: direct purchaser class settlement, In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, No. 18-md-02819 (E.D.N.Y.) (Hon.
Nina Gershon)$166 million: direct purchaser class settlement, In re Lidoderm Antitrust Litigation, MDL No. 2521 (N.D. Cal.) (Hon.
Denise J. Casper)$94 million: direct purchaser class settlement, In re Celebrex (Celecoxib) Antitrust Litigation, No. 14-cv-00361 (E.D.
Va.) (Hon. Arenda L. Wright Allen, Hon.
Douglas E. Miller)$146 million: direct purchaser class settlement, In re Aggrenox Antitrust Litigation, MDL No. 2516 (D.
Conn.) (Hon. Stefan Underhill)CAREER HIGHLIGHTS$453.85 million: largest U.S. antitrust settlement in 2022, In Re Glumetza Antitrust Litigation, No.
1:19-md-05822-WHA (N.D.C) (Hon. William Alsup)$340 million: second largest antitrust settlement in 2022, In re: Ranbaxy Generic Drug Application Antitrust Litigation, No. 1:19-md-02878, (D.
Patti B. Saris)Approximately $200 million: tort victim recoveries via bankruptcy plan, In re New England Compounding Pharmacy, Inc. Products Liability Litigation, MDL No.
2419 (D. Mass.) (Hon. Rya W.
Anita B. Brody)4% price reduction of most retail drugs: New England Carpenters Health Benefits Fund v. First DataBank, Inc., No.
05-cv-11148 (D. Mass.) (Hon. Patti B.
Saris)$350 million: consumers and third party payers, San Francisco Health Plan v. McKesson Corp., No. 08-cv-10843 (D.
Mass.) (Hon. Patti B. Saris)$25 million: State of Connecticut, In re Zyprexa Products Liability Litigation, MDL No.
1596 (E.D.N.Y.) (Hon. Jack B. Weinstein)EXPERIENCEHas led almost 20 generic delay cases, involving various theories, on behalf of both direct and end payers to settlement and distributions to classes (or aggregated groups)Helped develop the econometric model used to show the relationship between marketing and the opioid epidemic in the opioids MDL.
In re National Prescription Opiate Litigation, No. 17-md-02804 (N.D. Ohio) (Hon.
15-cv-11828 (D. Mass.) (Hon. Nathaniel M.
Mass.) (Hon. F. Dennis Saylor, IV; Hon.
1629 (D. Mass) (Hon. Patti B.
Patti B. Saris), over $250 million in settlements) and related litigation against First Databank, (New England Carpenters Health Benefits Fund v. First DataBank, Inc., No.
Saris), major price rollback on hundreds of drugs)Worked closely with consumer groups trying to bring down the prices of prescription drugs, including serving as lead counsel to the former Prescription Access Litigation (PAL) project, a large coalition of health care advocacy groups that fought illegal, loophole-based overpricing by pharmaceutical companies.Since 2002, has represented consumers, consumer groups, health plans, governments and institutions in complex class actions involving waste, fraud, and abuse in the pharmaceutical industry.Special Assistant Attorney General for the Commonwealth of Massachusetts and the states of New Hampshire and Rhode Island, including in ground-breaking litigation against tobacco industry (injunctive relief and recovery of more than $10 billion).Spent seventeen years at a large Boston firm handling large complex civil and criminal litigation. Voted Massachusetts Ten Leading Litigators — The National Law Journal CURRENT ROLE RECENT SUCCESS CAREER HIGHLIGHTS EXPERIENCE
